5 Oct 2017 15:18
5 October 2017
PDMR Share Dealings
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the global pharmaceutical and services group, announces that it was notified on 5 October 2017 that the following transactions took place.
Steve Glass, Chief Commercial Officer, has exercised a total of 32,858 nil cost options over ordinary shares of 0.1 pence each in the Company. The options have been satisfied by shares from the Clinigen Group Employment Benefit Trust. He has subsequently sold 15,498 ordinary shares of 0.1 pence each in the Company at a price of 1147 pence per share in order to meet the expected tax obligations.
Following these transactions, Mr Glass's total beneficial interest in the Company is 17,360 ordinary shares representing approximately 0.02 per cent of the current issued share capital.
Separately, Debbie Ainge, Chief Operating Officer, has exercised a total of 9,471 nil cost options over ordinary shares of 0.1 pence each in the Company. The options have been satisfied by shares from the Clinigen Group Employment Benefit Trust. She has subsequently sold 9,471 ordinary shares of 0.1 pence each in the Company at a price of 1150 pence per share.
Following these transactions, Mrs Ainge's total beneficial interest in the Company is 10,254 ordinary shares representing approximately 0.01 per cent of the current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Steve Glass | |
2 | Reason for the notification | ||
a) | Position/status | Chief Commercial Officer / PDMR | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | 1. The exercise of 32,858 options over ordinary shares in the Company following the vesting of an award granted under the Long Term Incentive Plan. 2. The sale of 15,498 ordinary shares in the Company made in order to meet expected tax obligations arising from the transaction described in 1. | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
1147p | 15,498 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
15,498 1147p £177,762 | |
f) | Date of the transaction | 4 October 2017 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Debbie Ainge | |
2 | Reason for the notification | ||
a) | Position/status | Chief Operating Officer / PDMR | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | 1. The exercise of 9,471 options over ordinary shares in the Company following the vesting of an award granted under the Long Term Incentive Plan. 2. The sale of 9,471 ordinary shares in the Company. | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
1150p | 9,471 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
9,471 1157p £108,917 | |
f) | Date of the transaction | 4 October 2017 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
-Ends-
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate Broking) |
|
| |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinical Trial Services
Clinigen is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials.
Unlicensed Medicines
Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides 'on-demand' access globally to medicines which remain unlicensed at the point of care.
Commercial Medicines
The Group acquires global rights to niche hospital-only and critical care products, revitalising these assets around the world and returning them back to sustained growth. The Group also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
For more information on Clinigen, please visit www.clinigengroup.com